Tag Archives: Celgene

BMS deal quest gets a boost as Celgene swats aside another Revlimid patent challenge

Much of the investor doubt surrounding Bristol-Myers Squibb’s $ 74 billion Celgene buyout centers on the multiple myeloma blockbuster Revlimid—namely, whether its remaining patents can stand up to legal challenges. But the companies just scored a win in that department. Thursday, the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) decided not… Read More »

Bristol-Myers yanked its Celgene bid days before deadline—and got a better price

On Dec. 10, Bristol-Myers Squibb made what it said was its final offer to acquire Celgene. But it turns out that wasn’t the case. It ended up scoring a better deal instead. Just days before a Jan. 2 deadline Bristol-Myers itself had set for wrapping up an agreement, the New Jersey drugmaker pulled that proposal—$ 57… Read More »